News Conference News EuroPCR 2025 Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI Michael O'Riordan May 23, 2025
News Daily News Take Heed of Sex Differences in Peripheral Vascular Disease: AHA Michael O'Riordan March 13, 2025
News Opinion Editor's Corner TCT 2024 What’s Going to Be Big at TCT 2024? Michael O'Riordan October 17, 2024
News Conference News ISET 2024 How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy Caitlin E. Cox January 24, 2024
News Daily News Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel L.A. McKeown August 23, 2023
News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Conference News SCAI 2022 SAFE-PAD Provides More Long-term Safety Data for Paclitaxel L.A. McKeown May 22, 2022
News Daily News Percutaneous Axillary Access: SCAI Calls for Best Practices Caitlin E. Cox April 20, 2022
News Conference News ACC 2022 Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD L.A. McKeown April 04, 2022
News Daily News Skipping Low-Value Cardiovascular Care Could Save Billions: AHA Michael O'Riordan March 01, 2022
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Daily News FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited L.A. McKeown January 12, 2021
News Opinion Editor's Corner Envision Change: A Different Future for Cardiology, Medicine, Research, and Health Shelley Wood December 29, 2020
News Conference News VIVA 2020 As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice L.A. McKeown November 27, 2020
News Daily News ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency L.A. McKeown July 02, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020